Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,792
-18.81%
|
$494,592
$276.42 P/Share
|
|
Mar 28
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,885
-17.38%
|
$520,260
$276.42 P/Share
|
|
Mar 28
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,648
-12.15%
|
$454,848
$276.42 P/Share
|
|
Mar 28
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
6,286
-10.76%
|
$1,734,936
$276.42 P/Share
|
|
Mar 28
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,883
-11.76%
|
$519,708
$276.42 P/Share
|
|
Mar 28
2022
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,360
-10.8%
|
$651,360
$276.42 P/Share
|
|
Mar 27
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,822
+37.97%
|
-
|
|
Mar 27
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,241
+30.8%
|
-
|
|
Mar 27
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Grant, award, or other acquisition
|
Direct |
4,241
+28.11%
|
-
|
|
Mar 27
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,707
+21.47%
|
-
|
|
Mar 27
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Grant, award, or other acquisition
|
Direct |
14,144
+19.49%
|
-
|
|
Mar 27
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
4,241
+20.94%
|
-
|
|
Mar 27
2022
|
Lance Berberian EVP, CIO & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
5,310
+19.54%
|
-
|
|
Mar 25
2022
|
R Sanders Williams Director |
SELL
Open market or private sale
|
Direct |
572
-8.17%
|
$155,584
$272.98 P/Share
|
|
Mar 25
2022
|
Kathryn E Wengel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
603
+50.0%
|
-
|
|
Mar 10
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
249
-49.9%
|
$65,238
$262.21 P/Share
|
|
Feb 16
2022
|
Peter M Neupert Director |
BUY
Open market or private purchase
|
Direct |
3,500
+11.21%
|
$920,500
$263.8 P/Share
|
|
Feb 15
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
207
-3.77%
|
$56,511
$273.98 P/Share
|
|
Feb 15
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
207
-3.04%
|
$56,511
$273.98 P/Share
|
|
Feb 14
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-1.38%
|
$20,944
$272.68 P/Share
|
|
Feb 14
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-1.12%
|
$20,944
$272.68 P/Share
|
|
Feb 14
2022
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-2.32%
|
$217,328
$272.68 P/Share
|
|
Feb 14
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-1.08%
|
$29,376
$272.68 P/Share
|
|
Feb 14
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
277
-0.62%
|
$75,344
$272.68 P/Share
|
|
Feb 14
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
778
-3.12%
|
$211,616
$272.68 P/Share
|
|
Feb 14
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
261
-6.52%
|
$70,992
$272.68 P/Share
|
|
Feb 12
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
284
+4.85%
|
-
|
|
Feb 12
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
284
+3.96%
|
-
|
|
Feb 12
2022
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,708
+7.08%
|
-
|
|
Feb 12
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
317
+3.08%
|
-
|
|
Feb 12
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
940
+2.07%
|
-
|
|
Feb 12
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,638
+9.25%
|
-
|
|
Feb 12
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
867
+18.46%
|
-
|
|
Feb 07
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
218
-3.96%
|
$60,386
$277.38 P/Share
|
|
Feb 07
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
204
-3.0%
|
$56,508
$277.38 P/Share
|
|
Feb 04
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
53
-4.29%
|
$14,681
$277.48 P/Share
|
|
Feb 04
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150
+10.82%
|
-
|
|
Feb 04
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-1.47%
|
$22,714
$277.48 P/Share
|
|
Feb 04
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+5.1%
|
-
|
|
Feb 04
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-14.26%
|
$22,991
$277.48 P/Share
|
|
Feb 04
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
267
+31.45%
|
-
|
|
Feb 04
2022
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-5.81%
|
$23,545
$277.48 P/Share
|
|
Feb 04
2022
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
280
+16.07%
|
-
|
|
Feb 04
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
152
-2.18%
|
$42,104
$277.48 P/Share
|
|
Feb 04
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+7.45%
|
-
|
|
Feb 04
2022
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-7.89%
|
$391,124
$277.48 P/Share
|
|
Feb 04
2022
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,507
+16.39%
|
-
|
|
Feb 04
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
165
-1.68%
|
$45,705
$277.48 P/Share
|
|
Feb 04
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+5.4%
|
-
|
|
Feb 04
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
286
-0.65%
|
$79,222
$277.48 P/Share
|